Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

To join this study, you would need to be a woman aged 18 or older with advanced or returning womb cancer that doctors cannot remove with surgery. Your cancer also needs to have a specific genetic feature called 'mismatch repair deficiency' (dMMR).

You generally shouldn't have had chemotherapy for this advanced or returning cancer before. However, there are a few exceptions, such as if you had chemotherapy for a different reason and your cancer came back much later (at least 6 months), or if you had radiation treatment previously. It's also important to be well enough to take part, meaning you can do most of your daily activities without much help.

There are also some other important checks, for example, if you are able to become pregnant, you would need to use effective contraception during and for some time after the study treatment. The study team will review all your medical information carefully to make sure it's safe and appropriate for you to participate.

If you decide to take part in this study, you would receive either the new drug, pembrolizumab, or a combination of standard chemotherapy drugs (carboplatin and paclitaxel or similar options). The treatment would be given at the hospital through an IV (into a vein). During the study, you would have regular appointments for check-ups, blood tests, and scans (like CT scans) to see how you're responding to the treatment and to monitor for any side effects.

The exact number of visits and the total length of time you'd be in the study can vary. You would continue treatment as long as it is working for you and you are tolerating it well. After the treatment period, there would be a follow-up phase where doctors would continue to monitor your health. Your study doctor and nurse will explain the full schedule and what to expect in detail.